Different neurodegenerative conditions can have complex, overlapping clinical presentations
that make accurate diagnosis during life very challenging. For this reason, confirmation
of the clinical diagnosis still requires postmortem verification. This is particularly
relevant for clinical trials of novel therapeutics where it is important to ascertain
what disease and/or pathology modifying effects the therapeutics have had. Furthermore,
it is important to confirm that patients in the trial actually had the correct clinical
diagnosis as this will have a major bearing on the interpretation of trial results.
Here we present a simple protocol for pathological assessment of neurodegenerative
changes.
